Tyra Biosciences, Inc.TYRA stock score: 31/100
$19.73 · +0.61% · Scored Nov 19, 2026
- Technical
- 38
- Fundamental
- 30
- News
- 54
The reading
Tyra Biosciences (TYRA) scores 31 out of 100, which reads bearish, higher than 5% of Healthcare stocks and 7% of the 4,118 US stocks we score.
The composite weights fundamentals 80% and technicals 20%: fundamentals read 30, technicals 38.
Among the fundamentals, Quick Ratio at 100 and Price Target at 100 score highest, while Return on Equity (ROE) at 0 weighs the most against it.
On the daily chart, trend-following indicators average 24 and contrarian oscillators 65 — a split worth reading before trusting the technical total.
News sentiment is neutral at 54; it is shown, not counted in the composite.
Since Aug 22, 2026 the composite has ranged from 31 to 47, and it is down 11 points over the period.
About Tyra Biosciences
Tyra Biosciences (TYRA) is a clinical-stage biotechnology company based in Carlsbad, California, that develops precision drugs aimed at fibroblast growth factor receptors, a family of proteins that drive some cancers and genetic growth disorders. Its lead candidate, dabogratinib, is an oral drug designed to block FGFR3 selectively while sparing related receptors, which may limit the side effects seen with broader FGFR inhibitors. The company is developing dabogratinib in three areas: intermediate-risk non-muscle invasive bladder cancer, low-grade upper tract urothelial cancer and achondroplasia, the most common form of dwarfism, where it has received orphan drug and rare pediatric disease designations. It has stepped back from metastatic bladder cancer to focus on these indications. Tyra has no product revenue and funds research with cash raised from investors.
In achondroplasia, Tyra competes with BioMarin, which sells Voxzogo, as well as BridgeBio and Ascendis Pharma, which are developing other treatments. In bladder cancer it competes with Johnson & Johnson’s FGFR-targeted products and with other therapies for early-stage disease. Its edge rests on an oral, FGFR3-selective drug that could be given as a pill in both cancer and a pediatric bone disorder, along with in-house structure-based drug design. Investors who follow TYRA stock tend to watch clinical data from its bladder cancer and achondroplasia trials. Dose escalation progress and safety findings are closely followed. Cash runway and plans for late-stage studies are other factors.
What’s driving the score
The strongest and weakest of the scorers that count toward TYRA’s composite. Each returns 0–100, higher is more bullish — including metrics where low is good, like P/E.
Fundamental
30Pulling it up
- Quick Ratio100
Quick ratio measures a company's ability to meet short-term obligations with liquid assets.
- Price Target100
Price target score compares the current stock price to analyst consensus targets.
Current assets divided by current liabilities: the ability to pay short-term bills.
Holding it back
Return on Equity (ROE) measures how efficiently a company generates profits from shareholder equity.
Return on Assets (ROA) shows how efficiently a company uses its assets to generate profit.
Return on total capital: net income divided by debt plus equity, for the latest year.
26 weighted scorers; 13 had no data today and are left out rather than counted as zero.
Technical · daily
29Pulling it up
Candlestick patterns recognize specific price formations that historically suggest continuation or reversal.
Stochastic RSI combines Stochastic and RSI indicators for enhanced sensitivity to overbought/oversold conditions.
Williams %R (14-period) measures where the current price sits within the recent high-low range.
Holding it back
Simple Moving Average (200-period) is the most widely followed long-term trend indicator.
Parabolic SAR (Stop and Reverse) provides trailing stop levels that follow price trends.
Simple Moving Average (100-period) provides a longer-term perspective on price trends.
62 weighted scorers; 3 had no data today and are left out rather than counted as zero.
News · shown, not counted
- Global News
- 54
Technical score by timeframe
| Chart | Score | Weight |
|---|---|---|
| Hourly | 54 | 1 |
| Daily | 29 | 3 |
| Weekly | 34 | 2 |
| Monthly | 48 | 2 |
Composite score, last 90 days
Show the daily numbers
| Date | Composite |
|---|---|
| Nov 19, 2026 | 31 |
| Nov 18, 2026 | 31 |
| Nov 17, 2026 | 31 |
| Nov 16, 2026 | 31 |
| Nov 15, 2026 | 32 |
| Nov 14, 2026 | 32 |
| Nov 13, 2026 | 32 |
| Nov 12, 2026 | 31 |
| Nov 11, 2026 | 40 |
| Nov 10, 2026 | 42 |
| Nov 8, 2026 | 41 |
| Nov 7, 2026 | 41 |
| Nov 6, 2026 | 40 |
| Nov 5, 2026 | 40 |
| Nov 4, 2026 | 42 |
| Nov 3, 2026 | 43 |
| Nov 2, 2026 | 43 |
| Nov 1, 2026 | 41 |
| Oct 30, 2026 | 41 |
| Oct 29, 2026 | 42 |
| Oct 28, 2026 | 41 |
| Oct 27, 2026 | 42 |
| Oct 26, 2026 | 41 |
| Oct 25, 2026 | 40 |
| Oct 24, 2026 | 41 |
| Oct 23, 2026 | 41 |
| Oct 22, 2026 | 42 |
| Oct 21, 2026 | 40 |
| Oct 20, 2026 | 40 |
| Oct 19, 2026 | 38 |
| Oct 18, 2026 | 36 |
| Oct 17, 2026 | 36 |
| Oct 16, 2026 | 36 |
| Oct 15, 2026 | 36 |
| Oct 14, 2026 | 36 |
| Oct 13, 2026 | 36 |
| Oct 12, 2026 | 38 |
| Oct 11, 2026 | 38 |
| Oct 10, 2026 | 37 |
| Oct 9, 2026 | 39 |
| Oct 8, 2026 | 39 |
| Oct 7, 2026 | 39 |
| Oct 6, 2026 | 39 |
| Oct 5, 2026 | 39 |
| Oct 4, 2026 | 39 |
| Oct 3, 2026 | 39 |
| Oct 2, 2026 | 38 |
| Oct 1, 2026 | 39 |
| Sep 30, 2026 | 40 |
| Sep 29, 2026 | 41 |
| Sep 28, 2026 | 39 |
| Sep 27, 2026 | 40 |
| Sep 26, 2026 | 40 |
| Sep 25, 2026 | 39 |
| Sep 24, 2026 | 41 |
| Sep 23, 2026 | 42 |
| Sep 22, 2026 | 43 |
| Sep 21, 2026 | 44 |
| Sep 20, 2026 | 44 |
| Sep 19, 2026 | 44 |
| Sep 18, 2026 | 44 |
| Sep 17, 2026 | 42 |
| Sep 16, 2026 | 40 |
| Sep 15, 2026 | 44 |
| Sep 14, 2026 | 43 |
| Sep 13, 2026 | 40 |
| Sep 12, 2026 | 40 |
| Sep 11, 2026 | 40 |
| Sep 10, 2026 | 41 |
| Sep 9, 2026 | 39 |
| Sep 8, 2026 | 46 |
| Sep 7, 2026 | 46 |
| Sep 6, 2026 | 46 |
| Sep 5, 2026 | 47 |
| Sep 4, 2026 | 47 |
| Sep 3, 2026 | 42 |
| Sep 2, 2026 | 44 |
| Sep 1, 2026 | 43 |
| Aug 31, 2026 | 40 |
| Aug 30, 2026 | 41 |
| Aug 29, 2026 | 40 |
| Aug 28, 2026 | 40 |
| Aug 27, 2026 | 43 |
| Aug 26, 2026 | 46 |
| Aug 25, 2026 | 44 |
| Aug 24, 2026 | 42 |
| Aug 23, 2026 | 42 |
| Aug 22, 2026 | 42 |
Key facts
- Market cap
- $1.4B
- Sector
- Healthcare
- Industry
- Biotechnology
- Beta
- 0.67
- Risk grade (1–10)
- 8
- Next earnings
- Nov 10, 2026
Biotechnology peers
| Company | Market cap | Score |
|---|---|---|
| ANAB AnaptysBio | $1.4B | 69 |
| RAPP Rapport Therapeutics | $1.4B | 32 |
| NBTX Nanobiotix | $1.4B | 48 |
| IMCR Immunocore Holdings | $1.4B | 51 |
| NUVB Nuvation Bio | $1.3B | 40 |
| NTLA Intellia Therapeutics | $1.3B | 33 |
Questions
What is TYRA's stock rating today?
TYRA scores 31/100 (Bearish) as of Nov 19, 2026: technical 38, fundamental 30, and news sentiment 54, which is shown but not counted. Scores are recomputed every night.
What does Tyra Biosciences do?
Tyra Biosciences (TYRA) is a clinical-stage biotechnology company based in Carlsbad, California, that develops precision drugs aimed at fibroblast growth factor receptors, a family of proteins that drive some cancers and genetic growth disorders. Its lead candidate, dabogratinib, is an oral drug designed to block FGFR3 selectively while sparing related receptors, which may limit the side effects seen with broader FGFR inhibitors.
Is TYRA stock a buy?
The score is not a buy or sell recommendation. A 31 says the technical and fundamental signals we measure lean bearish today, relative to every other stock scored the same way. Use the breakdown above to see why, and treat it as a starting point for your own research.
How is the TYRA score calculated?
88 weighted scorers feed it today: 26 fundamental, scored against Healthcare ranges, and 62 technical on the daily chart, with 4 timeframes blended into the technical total. Every scorer returns 0–100; missing data is left out, never counted as zero.
Scores are information, not investment advice. Computed from Yahoo Finance, Finnhub and Alpha Vantage data; technical indicators via TA-Lib. Past scores do not predict future returns.
Embed this score
A badge for a blog post, newsletter or README. It updates every night and links back here. More badges
HTML
<a href="https://stocksscores.com/stocks/tyra/"><img src="https://stocksscores.com/stocks/tyra/badge.svg" alt="TYRA stock score" height="20"></a>
Markdown
[](https://stocksscores.com/stocks/tyra/)